Skip to main content
OpenTrials
Completed

NCT Number: NCT01135368

Safety and Efficacy of Lansoprazole in Patients With Reflux Disease

The purpose of this study is to measure the safety, efficacy and quality of life of lansoprazole in patients with reflux disease over a five year period.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

About this study

Lansoprazole is currently approved in Germany for the treatment of erosive reflux esophagitis and active duodenal and gastric ulcer disease, and for long-term treatment including maintenance of healed reflux esophagitis and duodenal ulcer disease and treatment of pathological hypersecretory conditions such as Zollinger-Ellison syndrome.

This study was conducted to evaluate the safety, efficacy and quality of life of patients receiving up to five years of treatment with lansoprazole.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Had Gastro Esophageal Reflux disease with or without oesophagitis.
  • Had a history of heartburn at least for 5 days per week during the past 6 months or was receiving long-term treatment with a proton pump inhibitor and during two weeks (without proton pump inhibitor treatment) prior to enrolment.

Exclusion criteria

  • History of surgery of stomach or oesophagus.
  • Gastric ulcer (can be included after healing of gastric ulcer).
  • Duodenal ulcer (can be included after healing of duodenal ulcer).
  • Bleeding (melena, hematemesis).
  • Severe concomitant disease (cancer, cardiovascular, renal, hepatic diseases).
  • Barrett oesophagus with dysplasia.
  • Complicated esophagitis (oesophageal strictures or ulcers).
  • Treatment with proton pump inhibitor or Histamine receptor 2 (H2)antagonists within the previous two weeks.
  • Pregnancy, wish to become pregnant, breast feeding.
  • Treatment with non steroidal anti-inflammatory drugs, treatment with acetylsalicylic acid (aspirin) > 100 mg/day.

Treatment and study plan

Lansoprazole

Drug

Lansoprazole capsules

Other names: Prevacid, Helicid, Zoton, Inhibitol, Agopton, AG-1749

Primary outcomes

  1. Change From Baseline in Reflux Disease Symptom - Heartburn

    Time frame: Baseline and Week 8

    Heartburn symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients.

  2. Change From Baseline in Reflux Disease Symptoms - Acid Regurgitation

    Time frame: Baseline and Week 8

    Acid regurgitation symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients.

  3. Change From Baseline in Reflux Disease Symptom - Difficulty Swallowing

    Time frame: Baseline and Week 8

    Difficulty swallowing symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients.

  4. Change From Baseline in Reflux Disease Symptom - Pain in Upper Abdomen

    Time frame: Baseline and Week 8

    Pain in the upper abdomen symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients.

  5. Change From Baseline in Reflux Disease Symptom - Nausea & Vomiting

    Time frame: Baseline and Week 8

    Nausea and vomiting symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients.

  6. Change From Baseline in Reflux Disease Symptom - Cough & Sore Throat

    Time frame: Baseline and Week 8

    Cough and sore throat symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients.

  7. Change From Baseline in Endoscopic Healing of Erosive Reflux Disease as Assessed by Endoscopy

    Time frame: Baseline and Week 8

    Los Angeles Classification is used to grade the extension of changes in the oesophagus induced by reflux disease (Grade 0: normal aspect of mucosa; Grade A: ≥1 mucosal breaks no longer than 5 mm; Grade B: ≥1 mucosal breaks >5 mm long; Grade C: mucosal breaks extending between tops of two or more mucosal folds but are <75% of the circumference; Grade D: mucosal breaks ≥75% of the circumference). Healed defined as anything less than Grade A criteria. The shift table below summarizes the individual transitions in Los Angeles classification between Baseline (table columns) and Week 8 (table rows).

Secondary outcomes

  1. Change From Baseline in Enterochromaffin-like Cell Hyperplasia

    Time frame: Baseline and Year 5

    Enterochromaffin-like (ECL) cells were evaluated and classified by histopathological examinations as Normal, Simple (diffuse) hyperplasia, or Linear, chain producing hyperplasia.

    The shift table below summarizes the individual transitions in ECL-cell classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows) for all patients.

  2. Change From Baseline in Antrum Atrophy

    Time frame: Baseline and Year 5

    Atrophy was assessed by histopathological examination of cells biopsied from the antrum and classified according to the Sydney classification as mild, moderate, severe or none. The shift table below summarizes the individual transitions in atrophy classification (mild, moderate, severe or none) between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  3. Change From Baseline in Corpus Atrophy

    Time frame: Baseline and Year 5

    Atrophy was assessed by histopathological examination of cells biopsied from the corpus and classified according to the Sydney classification as mild, moderate, severe or none. The shift table below summarizes the individual transitions in atrophy classification (mild, moderate, severe or none) between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  4. Change From Baseline in Average Antrum Chronic Inflammation Score

    Time frame: Baseline and Year 5

    Chronic inflammation of the antrum was assessed by histopathology and graded according to the Sydney classification: 0 = None; 1 = mild; 2 = moderate; 3 = Severe

  5. Change From Baseline in Corpus Chronic Inflammation Score

    Time frame: Baseline and Year 5

    Chronic inflammation of the corpus was assessed by histopathology and graded according to the Sydney classification: 0 = None; 1 = mild; 2 = moderate; 3 = Severe.

  6. Change From Baseline in Antrum Intestinal Metaplasia

    Time frame: Baseline and Year 5

    Intestinal metaplasia was assessed by biopsy and histopathological examination of the antrum and classified according to the Sydney classification as mild, moderate, severe or none. The shift table below summarizes the individual transitions in intestinal metaplasia classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  7. Change From Baseline in Corpus Intestinal Metaplasia

    Time frame: Baseline and Year 5

    Intestinal metaplasia was assessed by biopsy and histopathological examination of the corpus and classified according to the Sydney classification as mild, moderate, severe or none. The shift table below summarizes the individual transitions in intestinal metaplasia classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  8. Change From Baseline in Blood Analysis - Testosterone

    Time frame: Baseline and Year 5

    The change between testosterone measured at year 5 in males including final visit and Testosterone measured at baseline.

  9. Change From Baseline in Blood Analysis - Luteinizing Hormone

    Time frame: Baseline and Year 5

    The change between luteinizing hormone measured at year 5 in males including final visit and luteinizing hormone measured at baseline.

  10. Change From Baseline in Blood Analysis - Follicle Stimulating Hormone

    Time frame: Baseline and Year 5.

    The change between follicle stimulating hormone (FSH) measured at year 5 in males including final visit and follicle stimulating hormone measured at baseline.

  11. Ophthalmologic Examination - Visual Acuity

    Time frame: Baseline and Year 5

    Visual Acuity was measured using the Snellen eye chart at a distance of 6 meters. Acuity is expressed as a ratio of the test distance (6 M) / the distance the average eye can see the letters on a certain line of the eye chart. Visual acuity of 1 is normal; an individual with acuity of 0.5 could only recognize an object at half the distance compared to an individual with normal acuity.

  12. Change From Baseline in Ophthalmologic Examination - Adaptation Without Glare

    Time frame: Baseline and Year 5

    Adaptation is the ability of the eye to adjust to various levels of darkness and light. Normal and pathological status of adaptation without glare was defined as follows:

    • Normal status: Contrast between 1:0.05 and 1:23.5.
    • Pathological status: Contrast = 0 or contrast > 1:23.5.

    The shift table below summarizes the individual transitions in the classification of adaptation without glare between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  13. Change From Baseline in Ophthalmologic Examination - Adaptation With Glare

    Time frame: Baseline and Year 5

    Adaptation is the ability of the eye to adjust to various levels of darkness and light. Normal and pathological status of adaptation with glare was defined as follows:

    • Normal status: Contrast between 1:0.05 and 1:23.5.
    • Pathological status: Contrast = 0 or contrast > 1:23.5.

    The shift table below summarizes the individual transitions in the classification of adaptation with glare between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  14. Change From Baseline in Ophthalmologic Examination - Accommodation

    Time frame: Baseline and Year 5

    Accommodation is the adjustment of the focal length of the eye lens to keep an object in focus on the retina as its distance from the eye varies, and is measured in diopters: Diopters = 1/(focal length).

  15. Change From Baseline in Ophthalmologic Examination - Color Vision

    Time frame: Baseline and Year 5

    Color vision was assessed by an Ophthalmologist and classified as normal or pathological. Pathological findings include abnormal color vision tests, color blindness and anomalous quotient. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in color vision classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  16. Change From Baseline in Ophthalmologic Examination - Cornea Assessment of Right Eye

    Time frame: Baseline and Year 5

    The cornea of the right eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as cataracts, corneal degeneration, opacity, scars or deposits. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in corneal classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  17. Change From Baseline in Ophthalmologic Examination - Cornea Assessment of Left Eye

    Time frame: Baseline and Year 5

    The cornea of the left eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as cataracts, corneal degeneration, opacity, scars or deposits. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in corneal classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  18. Change From Baseline in Ophthalmologic Examination - Lens Assessment of Right Eye

    Time frame: Baseline and Year 5

    The lens of the right eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5.

    Pathological classification includes abnormal findings such as cataracts, lenticular opacities, vacuoles or pseudophakia. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in lens classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  19. Change From Baseline in Ophthalmologic Examination - Lens Assessment of Left Eye

    Time frame: Baseline and Year 5

    The lens of the left eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5.

    Pathological classification includes abnormal findings such as cataracts, lenticular opacities, vacuoles or pseudophakia. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in lens classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  20. Change From Baseline in Ophthalmologic Examination - Vitreous Body Assessment of Right Eye

    Time frame: Baseline and Year 5

    The vitreous body of the right eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5.

    Pathological classification includes abnormal findings such as myodesopsia, vitreous opacities, degeneration, detachment or prolapse. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in vitreous body classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  21. Change From Baseline in Ophthalmologic Examination - Vitreous Body Assessment of Left Eye

    Time frame: Baseline and Year 5

    The vitreous body of the left eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5.

    Pathological classification includes abnormal findings such as myodesopsia, vitreous opacities, degeneration, detachment or prolapse. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in vitreous body classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  22. Change From Baseline in Ophthalmologic Examination - Assessment of Retinal Aspect of the Right Eye

    Time frame: Baseline and Year 5

    The retinal aspect of the right eye (such as color anomalies) was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as deep red ocular fundus, fundus myopicus, retinal disorders, exudates or pigmentation. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in retinal aspect classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  23. Change From Baseline in Ophthalmologic Examination - Assessment of Retinal Aspect of the Left Eye

    Time frame: Baseline and Year 5

    The retinal aspect of the left eye (such as color anomalies) was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as deep red ocular fundus, fundus myopicus, retinal disorders, exudates or pigmentation. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in retinal aspect classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  24. Change From Baseline in Ophthalmologic Examination - Assessment of Optic Nerve and Papilla of the Right Eye

    Time frame: Baseline and Year 5

    The optic nerve and papilla of the right eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as optic nerve cupping, optic nerve cup/disc ratio, or glaucomatous optic disc atrophy. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in optic nerve/papilla classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  25. Change From Baseline in Ophthalmologic Examination - Assessment of Optic Nerve and Papilla of the Left Eye

    Time frame: Baseline and Year 5

    The optic nerve and papilla of the left eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as optic nerve cupping, optic nerve cup/disc ratio, or glaucomatous optic disc atrophy. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in optic nerve/papilla classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  26. Change From Baseline in Ophthalmologic Examination - Assessment of Retinal Blood Vessels of the Right Eye

    Time frame: Baseline and Year 5

    The retinal blood vessels of the right eye were assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as retinal vascular disorder, retinopathy, and retinal hemorrhage. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in retinal blood vessel classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  27. Change From Baseline in Ophthalmologic Examination - Assessment of Retinal Blood Vessels of the Left Eye

    Time frame: Baseline and Year 5

    The retinal blood vessels of the left eye were assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as retinal vascular disorder, retinopathy, and retinal hemorrhage. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in retinal blood vessel classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  28. Change From Baseline in Ophthalmologic Examination - Assessment of Macula Lutea of the Right Eye

    Time frame: Baseline and Year 5

    The macula lutea of the right eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as maculopathy, retinal pigmentation, macular degeneration, diabetic retinopathy, retinal hemorrhage or aneurysm. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in macula lutea classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

  29. Change From Baseline in Ophthalmologic Examination - Assessment of Macula Lutea of the Left Eye

    Time frame: Baseline and Year 5

    The macula lutea of the left eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as maculopathy, retinal pigmentation, macular degeneration, diabetic retinopathy, retinal hemorrhage or aneurysm. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in macula lutea classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows).

Sponsors and collaborators

Lead sponsor

Takeda

Industry

Registry information

Official study title

Safety and Efficacy of Lansoprazole in Patients With Reflux Disease. An Open, Single Arm, Long-term Study

Important dates

Study start
2002
Primary completion
2008
Study completion
2008
First posted
Jun 2, 2010
Registry last updated
Sep 3, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.